IGF-1 LR3 (Long R3 IGF-I): Structure, IGF-1R Signaling, and the Serum-Free Culture Record — A 2026 Research Guide

Most of the compounds covered in this Research Hub reached laboratories by way of the research-chemical market. IGF-1 LR3 arrived by a different route. Long R3 IGF-I was engineered in the early 1990s as a protein-engineering exercise — an attempt to separate receptor binding from binding-protein sequestration in insulin-like growth factor 1 — and it became, and remains, a commercial cell-culture reagent used in industrial bioprocessing to grow mammalian cells in serum-free media. That history gives it something few peptides in this category have: a large, non-anecdotal literature generated by people who were measuring cell density and protein titer, not outcomes. This guide summarizes the molecular profile, the receptor- and pathway-level mechanism, and the published preclinical and in-vitro record as it stands in 2026.

The information below describes in-vitro and preclinical laboratory research only. It is not medical guidance, and none of the findings described here establish safety or efficacy in humans.

Section 1 — Molecular Profile

IGF-1 LR3 is a recombinant analog of human insulin-like growth factor 1, not a synthetic peptide in the conventional sense. It is produced by recombinant expression — historically in Escherichia coli as a fusion protein, and more recently in yeast systems — rather than by solid-phase synthesis, which has consequences for how identity and purity are established analytically.

Key identifiers used in the literature and on analytical documentation:

• Compound name: IGF-1 LR3; Long R3 IGF-I; Long-[Arg3]-IGF-I; LR3 IGF-1
• CAS number: 946870-92-4
• Molecular formula: C400H625N111O115S9
• Molecular weight: approximately 9,117.6 Da (~9.1 kDa)
• Length: 83 amino acid residues, single polypeptide chain
• Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA
• Class: recombinant growth-factor analog; IGF-1 receptor agonist
• Structural reference: PDB entry 3LRI (solution structure of long-[Arg3]IGF-I)

Two engineered modifications distinguish it from native IGF-1, and both are deliberate. First, the native 70-residue IGF-1 sequence is extended at the N-terminus by a 13-residue peptide, MFPAMPLSSLFVN — an artifact of the original fusion-protein expression strategy that was retained because it proved functionally useful. Second, the glutamic acid at position 3 of the native sequence is replaced with arginine (the E3R substitution). The “Long” refers to the extension; the “R3” refers to the substitution. Together they yield an 83-residue molecule that retains agonist activity at the type 1 IGF receptor while binding the IGF binding proteins with substantially reduced affinity.

That second property is the whole point of the molecule. In any biological fluid or conditioned culture medium, native IGF-1 is largely bound by a family of six high-affinity IGF binding proteins (IGFBP-1 through IGFBP-6), which sequester it and control how much is free to engage the receptor. Reducing binding-protein affinity increases the bioavailable free fraction of the analog in the same medium — which is why a cell-culture supplement built on this scaffold is active at far lower concentrations than insulin or native IGF-1 in the same system.

The three-dimensional consequences of the modifications have been characterized directly. Solution NMR work published in 1997 and 2000 established the secondary structure and backbone dynamics of long-[Arg3]IGF-I and found the core IGF-1 fold preserved, with the N-terminal extension behaving as a flexible, largely disordered appendage rather than reorganizing the folded domain. That is a useful result for interpreting binding data: the analog is not a structurally novel protein, it is IGF-1 with an added disordered tail and a single charge substitution in a region that matters for IGFBP contact.

Section 2 — Mechanism

All activity described here is at the receptor and pathway level, in defined experimental systems.

Receptor engagement. IGF-1 LR3 is an agonist at the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase assembled as a disulfide-linked α2β2 heterotetramer. Ligand binding to the extracellular α-subunits drives a conformational change that activates the intracellular β-subunit kinase domains, which trans-autophosphorylate on tyrosine residues in the activation loop. Because IGF-1R and the insulin receptor (IR) share substantial homology and can form hybrid receptors, IGF-1 analogs are studied for activity at both; comparative work in Chinese hamster ovary cells found that Long R3 IGF-I activated both IGF-1R and IR in a dose-responsive manner, and did so more strongly at low concentrations than either insulin or native IGF-1.

Proximal substrates. Activated IGF-1R phosphorylates two principal classes of adaptor: the insulin receptor substrate proteins (IRS-1, IRS-2) and the Src-homology collagen protein (Shc). These are the branch point from which the two canonical downstream cascades diverge.

PI3K/Akt/mTOR. Phosphorylated IRS-1 recruits phosphoinositide 3-kinase, which converts PIP2 to PIP3 and enables Akt activation. Akt in turn phosphorylates a wide substrate set including GSK3β, the FOXO transcription factors, and the mTOR complex. In cultured cells this arm is the one most associated with the anti-apoptotic and protein-synthesis-associated signaling that makes the analog useful as a media supplement — suppression of apoptotic signaling extends viable culture duration, and mTOR-associated signaling is linked to translational output.

Ras/MAPK/ERK. Phosphorylated Shc recruits the Grb2/SOS complex, activating Ras, then RAF, MEK, and ERK. Phosphorylated ERK translocates to the nucleus and acts on transcriptional programs through effectors such as MYC and ELK. This is the arm conventionally associated with cell-cycle progression and proliferation in cell-culture models.

IGFBP evasion as a mechanism, not an effect. The distinguishing mechanism of the LR3 analog is not what it does at the receptor — that is IGF-1’s mechanism — but how much of it reaches the receptor. The E3R substitution and N-terminal extension reduce affinity for the IGFBPs, so in a system where binding proteins are present and actively secreted by the cells under study, a larger free fraction remains available. The 1992 Francis work that introduced these analogs framed the result exactly this way: relative biological potency was governed more by binding-protein interaction than by receptor affinity per se.

Throughout the literature these are described as mechanisms the analog has been studied for and researched for — IGF-1R activation, IRS-1/Shc phosphorylation, PI3K/Akt and MAPK/ERK engagement, reduced IGFBP sequestration — not as demonstrated clinical effects in humans.

Section 3 — Preclinical and In-Vitro Research Data

The in-vitro dataset for this analog is unusually concrete, because much of it was generated for bioprocess development where the readouts are quantitative and commercially audited.

In Chinese hamster ovary cell culture — the workhorse system for recombinant protein manufacture — Long R3 IGF-I has been reported to support growth and recombinant protein production in serum-free media at concentrations at least 200-fold lower than those required for insulin to achieve comparable support. Manufacturer-published bioprocess data report volumetric productivity improvements on the order of 62% over unsupplemented serum-free culture and roughly 40% over insulin-supplemented culture in CHO systems, with the mechanism attributed to a combination of proliferative signaling and reduced apoptosis extending viable culture duration.

In HEK293 cells, a 2006 study in Molecular Biotechnology compared Long R3 IGF-I directly against insulin in serum-free suspension culture and reported the analog to be the more potent alternative at substantially lower molar input, consistent with the CHO findings and with the IGFBP-evasion rationale.

Receptor-level work in CHO cells examined which receptors are actually being engaged, comparing insulin, native IGF-I, and Long R3 IGF-I across IGF-1R and IR activation and downstream second-messenger readouts. The finding that the analog produced greater activation of both receptors at lower concentrations is the mechanistic counterpart to the productivity data.

Expression-system work has continued into the current decade. A 2023 study in Applied Microbiology and Biotechnology reported recombinant expression of both IGF-1 and LR3 IGF-1 as xylanase fusion proteins in Pichia pastoris, part of an ongoing effort to produce correctly folded analog at scale outside bacterial systems — relevant to researchers because expression host affects folding, disulfide pairing, and the impurity profile that shows up on analytical testing.

Structural characterization rounds out the record. The 1997 FEBS Letters secondary-structure determination and the 2000 Journal of Biological Chemistry solution-structure and backbone-dynamics study together establish that the analog retains the native IGF-1 fold with a flexible N-terminal extension, and the coordinates are deposited publicly as PDB 3LRI.

What this dataset does not include is any human outcome evidence. The commercial and academic literature on Long R3 IGF-I is overwhelmingly cell-culture and bioprocess literature. That is a strength for a research-compound guide — the data are clean and quantitative — but it also means that any extrapolation beyond cell systems is unsupported by the record described here.

Section 4 — Published Literature

The following are real, published papers anchoring the Long R3 IGF-I record. Researchers should consult the primary sources rather than relying on summaries.

• Francis GL, Ross M, Ballard FJ, et al. (1992). “Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.” Journal of Molecular Endocrinology 8(3):213–223. The foundational paper for the LR3 design rationale.
• Francis GL, et al. (1992). “Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins.” Journal of Molecular Endocrinology 8(1). The companion expression and characterization paper.
• Laajoki LG, et al. (1997). “Secondary structure determination of 15N-labelled human Long-[Arg3]-insulin-like growth factor 1 by multidimensional NMR spectroscopy.” FEBS Letters 420(1):97–102.
• Laajoki LG, et al. (2000). “Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I.” Journal of Biological Chemistry 275(14):10009–10015. Coordinates deposited as PDB 3LRI.
• Voorhamme D, Yandell CA (2006). “LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells.” Molecular Biotechnology 34(2):201–204. PMID 17172665.
• Applied Microbiology and Biotechnology (2023). “Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.” Current-decade work on alternative expression hosts.
• “The signaling landscape of insulin-like growth factor 1” (2024). Journal of Biological Chemistry. PMID 39638246. A comprehensive current review of IGF-1R signaling architecture across tissue types — the best single reference for the pathway detail in Section 2.

Together these span the original engineering rationale, the structural consequences of the modifications, the serum-free culture performance data, modern expression work, and the contemporary understanding of the receptor signaling network the analog acts on.

Section 5 — Research Applications

In laboratory settings, IGF-1 LR3 appears most often as a defined-medium supplement and as a pharmacological probe of IGF-1R signaling. Reported in-vitro applications include supporting proliferation and viability of CHO and HEK293 lines in serum-free and protein-free media; serving as an insulin substitute in serum-free adaptation workflows where IGFBP secretion would otherwise blunt native IGF-1; acting as a positive control for IGF-1R activation in phospho-Akt and phospho-ERK immunoblot assays; and functioning as a comparator in structural and binding studies of IGF-1/IGFBP interaction.

Several handling variables materially affect reproducibility. Because the analog is a folded protein with three disulfide bonds rather than a linear peptide, misfolding and disulfide scrambling are real failure modes — material that assays correctly by mass may still be partly inactive if folding is wrong, which is why bioactivity or receptor-activation data are more informative than mass alone. Lyophilized material is generally stored at −20°C, protected from light and moisture; reconstituted stocks are typically handled in small aliquots to avoid freeze-thaw cycling, and carrier protein is sometimes used to limit adsorptive loss at low working concentrations. Expression host should be documented as part of the material’s identity, since bacterial, yeast, and mammalian production give different impurity and folding profiles.

Endotoxin deserves particular attention in this compound class. The primary application is cell culture, and endotoxin contamination independently triggers inflammatory and stress signaling that will confound exactly the Akt and ERK readouts most researchers are measuring. A material without a stated endotoxin figure is not suitable for the work it is most often bought for.

Section 6 — How to Evaluate a Source

For a recombinant protein analog, the certificate of analysis carries more weight than it does for a short synthetic peptide, because more can go wrong that a purity percentage alone will not reveal. When evaluating any IGF-1 LR3 source, confirm:

• Identity by LC-MS, with an observed mass consistent with the expected ~9,117 Da for the 83-residue analog. This is the single most useful discriminator: native IGF-1 (70 residues, ~7,649 Da) and the LR3 analog are trivially distinguishable by mass, and a COA that reports the wrong mass is reporting the wrong molecule.
• Purity by HPLC, with a stated percentage and a visible chromatogram rather than a bare number. For a recombinant protein, ask whether the method resolves misfolded and aggregated species, not just small-molecule impurities.
• Endotoxin by USP <85> LAL, with an actual figure. Non-negotiable for cell-based work.
• Heavy metals by ICP-MS.
• Lot-specificity: the COA must correspond to the exact batch shipped, be dated, and name the accredited laboratory that performed the testing.
• Expression system, disclosed. It changes what the impurity profile means.

Market pricing context: research-grade IGF-1 LR3 is typically listed in 0.1 mg and 1 mg lyophilized vials, and the per-milligram spread across the market is wide — driven by expression system, stated purity grade, endotoxin qualification, and whether the vendor publishes lot-matched analytical data at all. That spread is not arbitrary; a bacterially expressed, unqualified preparation and a high-purity endotoxin-tested one are not interchangeable inputs for a serum-free culture experiment. Price is a poor proxy for quality in either direction, and the COA is where the actual difference becomes visible.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

Founding batches are documented end to end, and full analytical data files are available per lot. You can review current documentation in the COA library, read the underlying methodology on the verification standard page, or browse the full catalog in the shop.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.